{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+3&page=31",
    "query": {
      "intervention": "dose level 3",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 17835,
    "total_pages": 1784,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+3&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=dose+level+3&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T09:28:04.783Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03973333",
      "title": "Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Select Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "IMC-C103C",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Immunocore Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-05-17",
      "completion_date": "2023-09-25",
      "has_results": false,
      "last_update_posted_date": "2024-10-18",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03973333"
    },
    {
      "nct_id": "NCT06493552",
      "title": "Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma",
        "Metastatic Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "SEphB4-HSA",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Enfortumab vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vasgene Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 700,
      "start_date": "2025-03-15",
      "completion_date": "2034-08",
      "has_results": false,
      "last_update_posted_date": "2025-04-03",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06493552"
    },
    {
      "nct_id": "NCT04730258",
      "title": "A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelomonocytic Leukemia",
        "AML",
        "MDS",
        "CMML"
      ],
      "interventions": [
        {
          "name": "CFI-400945",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Treadwell Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2021-04-16",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04730258"
    },
    {
      "nct_id": "NCT01098838",
      "title": "Safety and Efficacy of LCL161 in Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "LCL161",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2008-11",
      "completion_date": "2011-01",
      "has_results": false,
      "last_update_posted_date": "2012-08-03",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 3,
      "location_summary": "Chapel Hill, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01098838"
    },
    {
      "nct_id": "NCT03259555",
      "title": "A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar I Disorder",
        "Manic Episode"
      ],
      "interventions": [
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 322,
      "start_date": "2017-09-14",
      "completion_date": "2019-01-02",
      "has_results": true,
      "last_update_posted_date": "2020-02-10",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 29,
      "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Culver City",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03259555"
    },
    {
      "nct_id": "NCT05818085",
      "title": "Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "ABP-671",
          "type": "DRUG"
        },
        {
          "name": "Allopurinol",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Atom Therapeutics Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "19 Years to 75 Years"
      },
      "enrollment_count": 300,
      "start_date": "2023-08-11",
      "completion_date": "2025-03-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 35,
      "location_summary": "Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Brooksville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05818085"
    },
    {
      "nct_id": "NCT00517543",
      "title": "A Study to Examine the Effect of Particle Size on Bioequivalence and Bioavailability",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)",
        "Rheumatoid Arthritis",
        "Atherosclerosis"
      ],
      "interventions": [
        {
          "name": "GW856553",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2007-08",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2010-10-14",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 1,
      "location_summary": "Tacoma, Washington",
      "locations": [
        {
          "city": "Tacoma",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00517543"
    },
    {
      "nct_id": "NCT00003416",
      "title": "S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "Up to 69 Years"
      },
      "enrollment_count": 9,
      "start_date": "1998-09",
      "completion_date": "2004-01",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 84,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003416"
    },
    {
      "nct_id": "NCT06552416",
      "title": "Safety of MT-401-OTS in Patients With Relapsed AML or MDS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia, in Relapse",
        "MDS"
      ],
      "interventions": [
        {
          "name": "MT-401-OTS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marker Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2025-06-16",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-11-13",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Tampa, Florida • Kansas City, Kansas",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06552416"
    },
    {
      "nct_id": "NCT02215538",
      "title": "OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "OROS methylphenidate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 47,
      "start_date": "2004-11",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2014-08-13",
      "last_synced_at": "2026-11-17T09:28:04.783Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02215538"
    }
  ]
}